Shiraz

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

This research investigates the use of a diagnostic test called fractional flow reserve derived from CT angiography NIFFR in patients with known or suspected chronic coronary syndrome CAD. It focuses on patients who have at least one coronary artery lesion with 50-70% narrowing. The study aims to see if NIFFR can identify lesions that are not significant and predict major heart-related events over a one-year period. Participants had coronary computed tomography angiography CCTA and invasive coronary angiography ICA with FFR measurements. The study included 250 patients with intermediate coronary lesions and NIFFR values above 0.80. Their coronary artery lesions were carefully measured and classified using advanced imaging software. The study groups compared patients with nonsignificant NIFFR and those with significant NIFFR values. Over one year, patients were followed closely, with visits every three months and phone calls to monitor for major adverse cardiovascular events MACE, including heart-related death, acute coronary syndrome, unexpected procedures to restore blood flow, and hospitalizations due to heart problems. Researchers collected detailed patient information including heart function, lesion characteristics, and cardiovascular risk factors. Outcomes such as MACE, bleeding, and shortness of breath were tracked to evaluate the diagnostic value of NIFFR in predicting heart health risks.

Researchers are evaluating the safety and feasibility of transplanting human embryonic stem cell-derived dopaminergic progenitor cells, called DopaCells, directly into the brains of patients with moderately severe Parkinsons disease. This phase I, open-label, multicenter trial aims to assess how well this approach can be performed and its safety profile in a small group of participants. Participants will receive a one-time surgical procedure where about 10 million DopaCells are transplanted bilaterally into the putamen region of the brain using a specialized microinjection device. After the surgery, patients will undergo immunosuppressive therapy with drugs including Basiliximab, Tacrolimus, and Prednisolone for one year to support cell survival. The study will be conducted across two centers with consistent surgical and treatment protocols. Participants will be monitored closely for at least 12 months after transplantation to evaluate safety and feasibility outcomes. This includes regular clinical assessments, laboratory tests, and imaging to track treatment effects and potential side effects. The research team will also assess efficacy outcomes and continue safety monitoring up to 60 months post-transplant. The total participant involvement includes screening, surgery, immunosuppressive therapy, and long-term follow-up under medical supervision.

Researchers are evaluating the safety and effectiveness of two antiplatelet treatments for patients with chronic coronary syndrome who undergo percutaneous coronary intervention PCI using drug-eluting stents. The trial compares ticagrelor alone against the standard dual therapy of aspirin and clopidogrel. The study aims to measure major adverse cardiovascular events MACE, including cardiac death, myocardial infarction, stent thrombosis, and the need for further revascularization within six months after PCI. Patients will be randomly assigned to one of two groups after diagnostic angiography but before stent placement. One group will receive conventional dual antiplatelet therapy consisting of aspirin 80 mg once daily and clopidogrel 75 mg once daily. The other group will receive ticagrelor monotherapy at 90 mg twice daily. Treatment will begin with a loading dose before stent insertion unless patients are already on maintenance therapy. The intervention period lasts for six months. Participants will be monitored throughout the study for cardiovascular events, bleeding, and adverse treatment reactions. The study includes detailed safety assessments, and outcomes such as stent thrombosis and MACE will be tracked for six months post-PCI. The trial uses a randomized, triple-blind design and involves follow-up within a registry at a cardiology clinic. The total participation time covers the initial procedure and six months of treatment and monitoring.